These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 29976154)

  • 1. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.
    Harris AR; Perez MJ; Munson JM
    BMC Cancer; 2018 Jul; 18(1):718. PubMed ID: 29976154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
    Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
    Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer.
    Chaudary N; Milosevic M; Hill RP
    Gynecol Oncol; 2011 Nov; 123(2):393-400. PubMed ID: 21839498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
    García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
    J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis in tumor lymphangiogenesis and lymphatic metastasis.
    Wang J; Huang Y; Zhang J; Wei Y; Mahoud S; Bakheet AM; Wang L; Zhou S; Tang J
    Clin Chim Acta; 2016 Oct; 461():165-71. PubMed ID: 27527412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor superfamily member 15 (Tnfsf15) facilitates lymphangiogenesis via up-regulation of Vegfr3 gene expression in lymphatic endothelial cells.
    Qin TT; Xu GC; Qi JW; Yang GL; Zhang K; Liu HL; Xu LX; Xiang R; Xiao G; Cao H; Wei Y; Zhang QZ; Li LY
    J Pathol; 2015 Nov; 237(3):307-18. PubMed ID: 26096340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3.
    Hsu MC; Pan MR; Hung WC
    Cells; 2019 Mar; 8(3):. PubMed ID: 30901976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer.
    Lala PK; Nandi P; Majumder M
    Cancer Metastasis Rev; 2018 Sep; 37(2-3):369-384. PubMed ID: 29858743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
    Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
    Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
    Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L
    J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXF2 deficiency permits basal-like breast cancer cells to form lymphangiogenic mimicry by enhancing the response of VEGF-C/VEGFR3 signaling pathway.
    Wang QS; He R; Yang F; Kang LJ; Li XQ; Fu L; Sun B; Feng YM
    Cancer Lett; 2018 Apr; 420():116-126. PubMed ID: 29409810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling.
    Ji H; Cao R; Yang Y; Zhang Y; Iwamoto H; Lim S; Nakamura M; Andersson P; Wang J; Sun Y; Dissing S; He X; Yang X; Cao Y
    Nat Commun; 2014 Sep; 5():4944. PubMed ID: 25229256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer.
    Wang C; Xu S; Tian Y; Ju A; Hou Q; Liu J; Fu Y; Luo Y
    Neoplasia; 2019 Apr; 21(4):413-427. PubMed ID: 30925417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.
    Tutunea-Fatan E; Majumder M; Xin X; Lala PK
    Mol Cancer; 2015 Feb; 14():35. PubMed ID: 25744065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fucoidan inhibits lymphangiogenesis by downregulating the expression of VEGFR3 and PROX1 in human lymphatic endothelial cells.
    Yang Y; Gao Z; Ma Y; Teng H; Liu Z; Wei H; Lu Y; Cheng X; Hou L; Zou X
    Oncotarget; 2016 Jun; 7(25):38025-38035. PubMed ID: 27203545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics.
    Ji RC
    Cancer Metastasis Rev; 2006 Dec; 25(4):677-94. PubMed ID: 17160713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
    Wen J; Fu AF; Chen LJ; Xie XJ; Yang GL; Chen XC; Wang YS; Li J; Chen P; Tang MH; Shao XM; Lu Y; Zhao X; Wei YQ
    Int J Cancer; 2009 Jun; 124(11):2709-18. PubMed ID: 19219913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis.
    Chen SM; Zhao CK; Yao LC; Wang LX; Ma YN; Meng L; Cai SQ; Liu CY; Qu LK; Jia YX; Shou CC
    Acta Pharmacol Sin; 2023 Jan; 44(1):189-200. PubMed ID: 35778489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.